Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 16, 2022; 10(29): 10535-10542
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10535
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10535
Table 1 The immunohistochemical markers of angiosarcoma, histiocytic sarcoma, and reported cases
| Immunohistochemical markers | AS | HS | Case 1 | Case 2 |
| CD4 | Positive | ∕ | Positive | |
| Lysozyme | Positive | Positive | Positive | Positive |
| CD45 | Positive | ∕ | Positive | |
| CD31 | Positive | Positive | Positive | Positive |
| ERG | Positive | Positive | Negative | |
| CD34 | Positive | Positive | Negative | |
| CD68 | Positive | Positive | Focally positive | Positive |
| CD163 | Positive | ∕ | Negative | |
| CD8 | Positive | Negative | ||
| S-100 | Positive | Negative | Negative | |
| CD21 | ∕ | Negative | ||
| CK | Positive | ∕ | Negative | |
| F8 | Positive | Positive | Positive | ∕ |
| SMA | Positive | Positive | ∕ | |
| Sox-10 | Negative | ∕ | ||
| Ki-67 | Positive, 5%-10% | Positive, 15%-20% | ||
| P53 | Positive | Negative |
- Citation: Luo H, Wang T, Xiao L, Wang C, Yi H. Multiple disciplinary team management of rare primary splenic malignancy: Two case reports. World J Clin Cases 2022; 10(29): 10535-10542
- URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10535.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10535
